Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

Moderna integrates extensive research and development with both in-house and partner manufacturing to rapidly develop and ...

As you might know, Moderna, Inc. (NASDAQ:MRNA) just kicked off its latest quarterly results with some very strong numbers.

Fintel reports that on November 10, 2025, B of A Securities maintained coverage of Moderna (NasdaqGS:MRNA) with a ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Thursday reported a loss of $200 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Therapeutics company Gilead Sciences (NASDAQ:GILD) jumped 3.4%. Is now the time to buy Gilead Sciences? Access our full ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee reports from Nvidia and Walmart this week. So far, the Q3 ea ...

As of Friday, November 07, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 18.38%, which has investors questioning ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee reports from Nvidia and Walmart this week. So far, the Q3 ea ...